Emergent BioSolutions Inc.
Organization details
- Legal name
- Emergent BioSolutions Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Gaithersburg
- Headquarters state / province
- Maryland
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- EBS
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0001367644
- EIN
- 14-1902018
Board of directors
-
Donald W. DeGolyer · DirectorSince 2023
-
Jerome M. Hauer · DirectorSince 2023
-
John D. Fowler Jr. · DirectorSince 2026
-
Joseph C. Papa · Director · President and CEOSince 2024
-
Kathryn C. Zoon · DirectorSince 2023
-
Keith Katkin · DirectorSince 2023
-
Louis W. Sullivan · DirectorSince 2023
-
Marvin L. White · DirectorSince 2023
-
Neal Franklin Fowler · DirectorSince 2023
-
Robert Kramer · Director · President and CEOSince 2023
-
Ronald Richard · DirectorSince 2023
-
Sujata Tyagi Dayal · DirectorSince 2023
-
Zsolt Harsanyi · Director · ChairmanSince 2023
Chief executives
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 0
-15.9% a year in revenue
20% of the scoring weight is on file. Figures cover December 2023 – December 2025.
Director election results
Annual meeting of April 29, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
92.3%
-
94.2%
-
95.3%
-
98.7%
Board connections
5 of this board's directors also sit on 6 other boards. 6 are in the same sector.
-
Aptevo Therapeutics Inc. Same sectorvia Marvin L. White and Zsolt Harsanyi
-
Candel Therapeutics Inc. Same sectorvia Joseph C. Papa
-
Eledon Pharmaceuticals Inc. Same sectorvia Keith Katkin
-
Milestone Pharmaceuticals Inc. Same sectorvia Joseph C. Papa
-
Syndax Pharmaceuticals Inc. Same sectorvia Keith Katkin
-
United Therapeutics Corporation Same sectorvia Louis W. Sullivan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $986,093
- 13 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 7, 2026 | Donald W. DeGolyer Director | Open-market sale | −17,800 | $7.09 | $126,202 |
| Oct 1, 2026 | Williams Paul Anthony Officer (SVP, Products Business) | Open-market sale | −3,000 | $6.53 | $19,590 |
| Jul 1, 2026 | Williams Paul Anthony Officer (SVP, Products Business) | Open-market sale | −3,000 | $8.40 | $25,200 |
| Jun 8, 2026 | Williams Paul Anthony Officer (SVP, Products Business) | Shares withheld for tax | −694 | $8.00 | $5,552 |
| Jun 8, 2026 | Richard S. Lindahl Officer (EVP, Chief Financial Officer) | Shares withheld for tax | −3,964 | $8.00 | $31,712 |
| Jun 8, 2026 | Glessner Coleen Officer (EVP, Quality & Ethics, and CPL) | Shares withheld for tax | −2,018 | $8.00 | $16,144 |
| Jun 8, 2026 | Hartzel William Officer (SVP, Bioservices) | Shares withheld for tax | −1,741 | $8.00 | $13,928 |
| May 1, 2026 | Sujata Tyagi Dayal Director | Open-market sale | −12,781 | $8.36 | $106,849 |
| May 1, 2026 | Donald W. DeGolyer Director | Open-market sale | −14,527 | $8.36 | $121,446 |
| May 1, 2026 | Kathryn C. Zoon Director | Open-market sale | −16,145 | $8.36 | $134,972 |
| May 1, 2026 | Sujata Tyagi Dayal Director | Open-market sale | −980 | $8.94 | $8,761 |
| May 1, 2026 | Donald W. DeGolyer Director | Open-market sale | −954 | $8.96 | $8,548 |
| May 1, 2026 | Kathryn C. Zoon Director | Open-market sale | −1,057 | $8.97 | $9,481 |
| Apr 30, 2026 | Sujata Tyagi Dayal Director | Grant or award | +25,344 | — | — |
| Apr 30, 2026 | Donald W. DeGolyer Director | Grant or award | +25,344 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Emergent BioSolutions Inc.
Who is the CEO of Emergent BioSolutions Inc.?
Joseph C. Papa has been Emergent BioSolutions Inc.'s President and CEO since February 2024.
How many directors are on Emergent BioSolutions Inc.'s board?
Emergent BioSolutions Inc.'s board has 13 directors: Donald W. DeGolyer, Jerome M. Hauer, John D. Fowler Jr., Joseph C. Papa, Kathryn C. Zoon, Keith Katkin, Louis W. Sullivan, Marvin L. White, Neal Franklin Fowler, Robert Kramer and 3 others.
Are Emergent BioSolutions Inc. insiders buying or selling shares?
Over the last 12 months, Emergent BioSolutions Inc. insiders made no open-market purchases and sold $986,093 of shares in 13 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="emergent-biosolutions-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.